Decreased neutralization of SARS-CoV-2 global variants by therapeutic anti-spike protein monoclonal antibodies

Monoclonal antibodies against the SARS-CoV-2 spike protein, notably, those developed by Regeneron Pharmaceuticals and Eli Lilly and Company have proven to provide protection against severe COVID-19. The emergence of SARS-CoV-2 variants with heavily mutated spike proteins raises the concern that the...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:bioRxiv
Main Authors: Tada, Takuya, Dcosta, Belinda M., Zhou, Hao, Vaill, Ada, Kazmierski, Wes, Landau, Nathaniel R.
Format: Artigo
Jezik:Inglês
Izdano: Cold Spring Harbor Laboratory 2021
Teme:
Article
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC7899448/
https://ncbi.nlm.nih.gov/pubmed/33619484
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1101/2021.02.18.431897
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki